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Consumption of anthocyanin-rich cherry juice for 12 weeks improves memory
and cognition in older adults with mild-to-moderate dementia
Abstract
Purpose Dietary flavonoids, including anthocyanins, may positively influence cognition and may be
beneficial for the prevention and treatment of dementia. We aimed to assess whether daily consumption
of anthocyanin-rich cherry juice changed cognitive function in older adults with dementia. Blood pressure
and anti-inflammatory effects were examined as secondary outcomes. Methods A 12-week randomised
controlled trial assessed cognitive outcomes in older adults (+70 year) with mild-to-moderate dementia (n
= 49) after consumption of 200 ml/day of either a cherry juice or a control juice with negligible
anthocyanin content. Blood pressure and inflammatory markers (CRP and IL-6) were measured at 6 and
12 weeks. ANCOVA controlling for baseline and RMANOVA assessed change in cognition and blood
pressure. Results Improvements in verbal fluency (p = 0.014), short-term memory (p = 0.014) and longterm memory (p ≤ 0.001) were found in the cherry juice group. A significant reduction in systolic (p =
0.038) blood pressure and a trend for diastolic (p = 0.160) blood pressure reduction was evident in the
intervention group. Markers of inflammation (CRP and IL-6) were not altered. Conclusion Inclusion of an
anthocyanin-rich beverage may be a practical and feasible way to improve total anthocyanin consumption
in older adults with mild-to-moderate dementia, with potential to improve specific cognitive outcomes.
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Abstract
Purpose: Dietary flavonoids, including anthocyanins, may positively influence cognition and
may be beneficial for the prevention and treatment of dementia. We aimed to assess whether
daily consumption of anthocyanin-rich cherry juice changed cognitive function in older
adults with dementia. Blood pressure and anti-inflammatory effects were examined as
secondary outcomes.
Methods: A 12-week randomised controlled trial assessed cognitive outcomes in older adults
(+70y) with mild to moderate dementia (n=49) after consumption of 200ml/day of either a
cherry juice or a control juice with negligible anthocyanin content. Blood pressure and
inflammatory markers (CRP, IL-6) were measured at 6 and 12 weeks. ANCOVA controlling
for baseline and RMANOVA assessed change in cognition and blood pressure.
Results: Improvements in verbal fluency (P=0.014), short term memory (P=0.014) and long
term memory (P=<0.001) were found in the cherry juice group. A significant reduction in
systolic (P=0.038) blood pressure and a trend for diastolic (P=0.160) blood pressure
reduction was evident in the intervention group. Markers of inflammation (CRP and IL-6)
were not altered.
Conclusion: Inclusion of an anthocyanin-rich beverage may be a practical and feasible way to
improve total anthocyanin consumption in older adults with mild to moderate dementia, with
potential to improve specific cognitive outcomes.
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Introduction
Plant-based foods form an integral component of the human diet and their consumption is
consistently linked to the maintenance of health and the prevention of a vast array of diseases
(1). A growing body of evidence has shown that phytochemicals, non-nutritive bioactive
compounds, contribute to the antioxidant activity of individual fruits and vegetables and are
consequently credited with the observed health benefits (2). Flavonoids are a class of
polyphenols that have been studied intensively and are categorised into six major classes:
anthocyanins, flavanols, flavanones, flavones, flavonols, and isoflavones (3). Flavonoids are
found in particularly high concentrations in fruits and vegetables, wine, tea and cocoa (4).
The consumption of flavonoids has been associated with a reduction in risk for
cardiovascular diseases and some cancers (5, 6) and more recently there has been attention
directed to their potential to protect against neurodegenerative diseases and improve
cognitive performance in older adults (7).
The sub-groups of flavanols, anthocyanins and flavanones have been shown to be the most
beneficial of the flavonoid family in terms of neuro-protection (8). Specifically, literature
investigating the impact of fruit flavonoids on cognitive and physical functioning is
predominately pre-clinical (9) and while promising, remains inconclusive. Much of the foodbased research has focused on flavonoid-rich blueberries and strawberries (9). The biological
actions of flavonoids on cognitive function have been attributed to a number of hypothesized
mechanisms. Their antioxidant actions assist to scavenge free radicals in the brain (8), while
their neuro-protective effects include protection of vulnerable neurons against inflammation,
enhancement of existing neuronal function, increased blood flow to the brain and
neurogenesis initiation in areas of the brain that are associated with cognition (10).
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Preliminary dietary supplementation studies have shown that blueberries (11) and concord
grapes (12, 13) improve aspects of memory in older adults over a 12 and 16 week
intervention. Cherries, both the sweet and tart varieties, are a rich source of anthocyanins and
to a lesser extent also contain flavan-3-ols and flavonols (14). Cherries have been found to
lower inflammation and scavenge nitrous oxide radicals within the body (15). However the
potential of cherry flavonoids to influence cognitive function has not been investigated,
despite them being a commonly consumed fruit in Australia (4) and other countries.
Research to date has investigated the cognitive enhancing effects of flavonoid-rich foods in
participants with both normal cognitive function (16) and people with mild cognitive
impairment (11-13) but effects in dementia patients remains under researched (17). In light of
projections indicating rapid increases in the prevalence of the dementia (18) and in the
absence of successful treatments, alternative measures to slow the development and
progression of dementia are imperative.
A randomised clinical trial was conducted to assess changes in cognitive function in older
adults with mild to moderate dementia after daily consumption of a feasible serving of
anthocyanin-rich cherry juice over 12 weeks. Secondary outcomes included antiinflammatory effects, changes in functional and physical ability and mood.
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Methods
Participants
Participants were recruited from a geriatric outpatient dementia clinic and residential aged
care facilities in the Illawarra region of New South Wales, Australia. Participants were aged
70 years or older and had been diagnosed as having mild to moderate dementia Alzheimer’s
type, as confirmed by the consultant geriatrician responsible for their clinical management
(JP). Exclusion criteria include non-English speaking, uncontrolled hypertension,
uncontrolled diabetes, any other unstable physical or mental health condition or dysphagia.
Written informed consent was obtained. For participants with cognitive impairment deemed
by their geriatrician to be too severe to provide informed consent, consent was provided by
family carers or guardians. Consenting participants (Table 1) were randomised to a treatment
group and randomised by computer-aided block randomisation, conducted by a statistician
that was independent to the research interface (MB) (Figure 1). All other researchers were
blinded to the grouping. This study was approved by the University of Wollongong Human
Research Ethics Committee and the Illawarra Shoalhaven Local Health Districts ethics
committee (HE11/175). This study was registered as a clinical trial through the Australian
New Zealand Clinical Trials Registry (ANZCTR) and was allocated the ACTRN:
ACTRN12614001298606.

Study Procedure
Over 12 weeks participants received 200ml/day of cherry juice (intervention arm) or
200ml/day of commercially prepared apple juice (control arm). Juice was delivered weekly,
by a research assistant not involved in data collection, to the homes of participants, chilled in

5

1L plastic bottles. Instructions were provided to participants and carers for the juice to be
consumed daily, at any time in one sitting, using a cup provided that indicated 200ml with a
fill line. A weekly calendar was provided with the juice, with daily check boxes ticked when
the juice was consumed. The sweet, Bing cherry juice was produced using a novel method
that aims to retain the phenolic bioactives, developed by a research company
(Agritechnology) based in Orange, NSW, Australia. The high antioxidant activity and
anthocyanin content of cherries is well retained in the juice which had a high Oxygen Radical
Absorbance Capacity (3200 µmol Trolox Equivalents/g) and contained 69 mg red pigments
(anthocyanins) per 100g of juice as determined by HPLC (19) (Table 2). The apple juice was
provided by Appledale, based in Orange, NSW, Australia (Table 2). Nutritional content of
the intervention and control juices are shown in Table 2. A serving size of 200ml per day was
determined as being a feasible quantity that could be consumed by an older adult with mildmoderate dementia, and was chosen in the absence of empirical research that highlights a
dose requirement for anthocyanin intake and cognitive outcomes. The serving size provided a
more feasible serving of juice than has been used in previous similar studies, where the
quantity of anthocyanin-rich beverages provided may exceed the amount that can be feasibly
achieved over the long term, especially by older adults living with a neurodegenerative
disease (11, 13). No change to regular diet was advised.
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Table 1: Baseline characteristics of participants in the study according to group
Characteristic

Control group

Intervention group

n=25, mean ± SD n=24, mean ± SD

Age (years)

80.6 ± 6.6

78.9 ± 5.2

BMI (kg/m2)

26.6 ± 3.5

25.7 ± 3.4

Current smokers (count)

1 (4%)

0 (0%)

Previous smokers (count)

10 (40%)

7 (29%)

Hand grip strength (kg)

52.1 ± 16.4

62.5 ± 16.1*

Mid arm circumference (cm)

26.9 ± 4.5

27.2 ± 4.1

Calf circumference

33.4 ± 3.7

34.9 ± 3.4

Education (years)

17.5 ± 3.2

18.2 ± 2.4

Mini Nutritional Assessment

23.4 ± 3.5

25.6 ± 2.8*

Instrumental Activities of Daily Living

5.7 ± 2.4

7.5 ± 0.8*

429.8 ± 384.2

599.0 ± 352.2

Flavonol intake (mg/day)

20.0 ± 13.2

32.9 ± 26.5

Flavone intake (mg/day)

0.3 ± 0.3

1.2 ± 1.7

Flavanone intake (mg/day)*

8.8 ± 16.4

11.7 ± 17.9*

Flavon-3-ol intake (mg/day)*

382.9 ± 379.6

518.9 ± 338.9*

Anthocyanin intake (mg/day)

13.1 ± 29.7

34.2 ± 55.6*

Total flavonoid intake (mg/day)

*P<0.05, for differences between groups.
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Enrolment

Assessed for eligibility
(n=56)
Excluded (n=7)
 Not meeting inclusion criteria
(cognition) (n=5)
 Declined to participate (n=1)
 Other reasons (n=1)
Randomized (n=49)

Allocation
Allocated to intervention (n= 24)
 Received allocated
intervention (n= 24)

Allocated to control (n= 25)
 Received allocated
control (n= 25)

Follow-Up
Lost to follow-up (n= 0)

Lost to follow-up (n= 0)

Discontinued intervention (n= 3)

Discontinued intervention (n= 4)



Indefinitely Hospitalized (n=1)



Study Burden (n=2)



Died (n=1)



Moved (n=1)



Study Burden (n=3)

Analysis
Analysed at baseline (n= 21)


Analysed at baseline (n= 21)


Excluded from analysis
at 6 and 12wk (n= 0)

Excluded from analysis
at 6 and 12wk (n= 0)

Figure 1. CONSORT flow diagram of enrolment, allocation, follow up and analysis.
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Table 2: Nutritional properties of intervention and control juice
Cherry Juice (100ml)

Apple Juice (100ml)

Energy

395kJ

180kJ

Protein

1.5g

0.1g

Fat Total

<0.2g

0.1g

Saturated

<0.2g

0.1g

Carbohydrate Total

21.0g

10.5g

Sugars

16.0g

9.3g

Dietary fibre

0.7g

0.0g

Sodium

<1mg

1.0mg

Oxygen Radial Absorbance Capacity

3200 µmol TE a/ g

15.55 µmol TEa/ g

Red Pigment (Anthocyanin) content

69 mg b

0.02mg c

a

Trolox Equivalent

b

Iland Method (19).

c

USDA database for the flavonoid content of selected foods (release 3.1) (14).
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Measurements
Outcome variables were measured at three time points: baseline, 6 weeks and 12 weeks with
all interviews conducted at the same time of the day (am). At baseline and 12 weeks
participants arrived fasting and a blood sample was collected by a trained phlebotomist. A
standardised breakfast was offered to participants (cereal, milk, banana, tea and/or coffee)
and they were instructed to consume the meal ad-libitum, before the remainder of the
interview was conducted. At 6 weeks, participants arrived at the clinic after having consumed
their usual breakfast at home.

At each interview, a questionnaire was administered by a single researcher, with the
assistance of a guardian or carer, where appropriate, reporting selected demographic
characteristics, tobacco use, and consumption of alcohol, supplements and medications.
Nutritional status was assessed using an interviewer-administered Mini Nutritional
Assessment (MNA) (20) and dietary intake, including flavonoid intake, was assessed using a
24hr dietary recall method, with the assistance of a carer or guardian. Dietary records were
entered into the FoodWorks dietary assessment programme to assess nutritional parameters
(Xyris Software, Highgate Hill, QLD, Australia, Version 5, 2007). To estimate usual
flavonoid intake, dietary records were cross-referenced with the 2013 USDA database for the
flavonoid content of selected foods release 3.1 (14). Resting BP and heart rate were measured
using an Omron HEM7200 Deluxe Automatic BP Monitor, while seated, in triplicate and
averaged. To monitor physical outcomes over 12 weeks, anthropometric measurements
included height, weight, and mid arm and mid-calf circumference. Lawton’s Instrumental
Activities of Daily Living Scale (IADL) (21) determined functional impairment and hand
grip strength was assessed using a digital Jamar handgrip dynamometer (Lafayette
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Instruments, Indiana, USA). The blood sample assessed changes in markers of inflammation
(C-reactive protein (CRP) and Interleukin-6 (IL-6) and plasma vitamin C levels. Blood
samples were prepared and stored at -80oC for batch analysis by an independent laboratory
where IL6 was measured by High Sensitivity cytokine panel (millipore), CRP was measured
by hsCRP (Kamiya), and Vitamin C by an in-house method.

Outcome assessment
Cognitive function was assessed using a battery of seven cognitive tests, including the Rey
Auditory Verbal Learning Test (RAVLT) (22, 23) , the self-ordered pointing task
(SOPT)(24), the Boston naming test (25), the trail making test (TMT) (26), digit span
backwards task (27) and category and letter verbal fluency (28). The RAVLT measured
verbal learning and memory by the participant learning a list of words over presentation-test
and delayed-test trials. The SOPT is a test of working memory, and the Boston naming test
assessed confrontational naming, related to semantic memory. The TMT A and B evaluated
executive function and the relative difference between B and A was used as the measure.
Digit span backwards task examined short-term memory storage and executive control
processes by requiring participants to repeat a series of numbers in the reverse order they
were given. Category and letter verbal fluency measured executive function, requiring
participants to recite as many words as possible that belonged to the category “animals” or
began with the letter “F” and “A”. The geriatric depression scale (GDS) (29) assessed mood
state.
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Statistical Analysis
Statistical analysis was conducted using SPSS statistical program (V17.0: 2006, SPSS, Inc.,
Chicago, II, USA). Analysis was completed using the full cohort that completed each of the
time points. Continuous data are described as the mean and standard deviation (SD) as
appropriate. Non-normally distributed variables were transformed and treated as normally
distributed. Baseline differences between the intervention and control group’s characteristics
and nutrition information were analysed by unpaired t-tests for continuous variables. A 2-way
repeated measures ANOVA analysed the effect of time, treatment, and time*treatment
interactions for blood pressure measurements at 6 and 12 weeks. Analysis of covariance
(ANCOVA) using the baseline data as a covariate was used to analyse the group effect at 6
and 12 weeks for all cognitive tasks, to isolate the effect of the intervention while controlling
for group differences at baseline. Repeated measures ANOVA assessed differences in
markers of inflammation and vitamin C at baseline and 12 weeks. A p value less than or
equal to 0.05 was considered to indicate statistical significance. Eta-squared (η2) values were
calculated to indicate the strength of the main effect. The Cohen’s f effect size estimates were
characterised as small (0·10), medium (0·25) and large (0·40) (30).
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Results
Forty-nine participants (24 female, 25 male) were recruited and seven participants withdrew
from the study (2 indefinitely hospitalised, 4 due to study burden and 1 moved away).
Participants were randomised into the control group (n=25) and intervention group (n=24)
(Figure 1).

Baseline:
No differences between groups were found for age, BMI and anthropometrics, years of
education or total flavonoid intake at baseline. Significant differences at baseline were found
between groups for measures of malnutrition, activities of daily living, and hand grip
strength.
Differences in habitual intake of several flavonoid subclasses was found between the groups,
according to a 24h recall administered at baseline (Table 1), with the intervention group
consuming more flavonoids than control subjects. Mean total flavonoid intake was estimated
as 510mg/day. Black tea (80%) was the most significant dietary source of total flavonoids
followed by green tea (7.5%), red wine (4.5%), apples (1.7%) and oranges (1.6%) with their
respective fruit juices. Flavonols contributed 5.15% of total flavonoid intake. Dominant
sources included black and green tea, onion, broccoli and apples. Flavones contributed the
smallest percentage (0.15%) with the major source being parsley. Total flavanone intake
provided 2% with major sources including oranges and orange juice, and lemons. Flavon-3ols contributed 88.1% of total intake, with black tea as the major source and wine and apples
contributing somewhat. Anthocyanidins (4.6%) were provided by red wine, red grapes and
bananas.
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At baseline, the only significant difference between the groups for nutrient intake was for
carbohydrates (p=0.023) and caffeine intake (p=0.03), with the intervention group with a
higher intake than the control.

Post-intervention:
A trend for improvement in most of the cognitive tasks is evident as shown by the mean
difference between baseline and 12 weeks for the intervention group only (Table 3). Analysis
of covariance showed significant improvement in cognitive performance in the intervention
group only (Figure 2), at 6 and 12 weeks for the Category Verbal Fluency task (p=0.014) ,
RAVLT total (p=0.014) , RAVLT delayed recall (p=0.005) and RAVLT 20 minute delayed
recall (p=<0.001) tasks. The effect sizes for Category Fluency (η2 = 0·711), RAVLT total (η2
= 0.713), RAVLT delayed recall (η2 = 0.433) were large and the effect size for RAVLT 20
minute delayed recall (η2 = 0.242) was moderate. No significant improvements from baseline
were found for cognitive performance tasks in the control group.
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Table 3: Mean scores for cognitive performance and mood by group a
Control group

Letter Verbal Fluency
(executive function)
Category Verbal Fluency
(executive function)
RAVLT total (I-V)
(learning and memory)
RAVLT delayed recall
(memory)
RAVLT 20m delayed recall
(memory)
Trail making task b

Intervention group

Baseline

12 weeks

Mean

Baseline

12 weeks

Mean

n=25

n=21

Difference

n=24

n=21

Difference

13.1 ±

13.1 ±

0.015 ±

18.9 ±

19.0 ±

7.5

7.9

0.4

11.0

10.3

8.4 ± 4.5

8.3 ± 4.7

-0.1 ±

11.9 ±

0.19

4.5

19.3 ±

17.5 ±

-1.8 ±

25.5 ±

29.1 ±

9.2

13.1

3.85

10.6

11.5

1.2 ± 1.9

1.4 ± 2.2

0.2 ± 0.4

0.7 ± 1.2

0 ± 0.07

0.72 ±
1.2
129.8 ±

128.6 ±

81.1

85.0

1.3 ± 1.3

1.6 ± 1.8

0.3 ± 0.5

2.3 ± 1.1

2.8 ± 1.1

0.5 ± 0

Boston naming task

33.1 ±

31.9 ±

(semantic memory)

15.5

13.6

7.3 ± 4.7

6.9 ± 3.5

(executive functioning)
Self-ordered pointing task
(working memory)
Digit span backwards task
(short-term memory)

Geriatric Depression Scale b
(mood)
a

-1.2 ± 4.0

-1.2 ± -1.8
-0.4 ± -1.2

2.3 ±
2.6
0.6 ±
1.0

13.4 ± 5.1

2.3 ± 2.6

1.6 ± 1.4

65.0

67.3

3.0 ±
1.0

0.0 ± -0.2

3.4 ± 1.2

0.4 ± 0.2

40.0 ±

13.1

13.6

4.5

-23.2 ± 2.32

0.6 ± 0.8

40.6 ±
6.9 ±

3.9 ± 0.88
1.6 ± 0.4

101.9 ±

1.0

1.9 ± 0.17

3.8 ± 2.9

125.1 ±
0.6 ±

0.13 ± 0.7

6.3 ± 4.3

-0.5 ± 0.5
-0.6 ± -0.2

Data are given as mean ± SD. Baseline refers to measures obtained at the pre-intervention

assessment. Final refers to measures obtained during the final week of the intervention.
Difference = final score (mean) less baseline score (mean).
b

A negative score is indicative of improved outcomes. Otherwise, a positive difference in

score indicates improved outcomes.
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**

Figure 2: Significant changes in category fluency (A), RAVLT total (B), RAVLT delayed recall (C) and RAVLT – 20minute delayed recall (D)
at 6 and 12 weeks post intervention
*p=<0.05**p=<0.001
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Table 4: Blood pressure and heart rate measurements according to group at baseline, 6 and 12 weeks a
Control group

Intervention group

Baseline

6 weeks

12 weeks

Baseline

6 weeks

12 weeks

n=25

n=21

n=21

n=24

n=21

n=21

Systolic BP*

140 ± 19.7

138.5 ± 12.3

137.0 ± 10.1

138.2 ± 16.4

133.7 ± 9.9

130.5 ± 12.2

Diastolic BP

80.6 ± 9.8

81.0 ± 8.0

81.3 ± 11.6

78.6 ± 11.7

77.0 ± 9.9

77.0 ± 12.6

Heart Rate

70.2 ± 10.2

70.2 ± 11.1

74.2 ± 11.8

67.9 ± 10.7

66.0 ± 7.2

67.5 ± 7.9

*p=<0.05
Data are given as mean (mmHg) ± SD.
a

Baseline refers to measures obtained at the pre-intervention assessment. 6 weeks and 12 weeks refers to measures obtained at these time points

during the intervention.
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Repeated measures ANOVA, with the baseline as a covariate, showed a significant difference
in systolic blood pressure (p=0.038) at 6 and 12 weeks post baseline, with a similar trend
evident for diastolic blood pressure (p=0.160) in the intervention group (Table 4). No
significant differences in blood pressure are evident for the control group.
At follow up, there were no significant between-group differences in nutrient intake or for
change in nutrient intake from baseline.
Repeated Measures ANOVA showed no significant difference between the intervention and
control groups for serum vitamin C, IL-6 or CRP at baseline or 12 weeks (Table 5). There
were no improvements in serum vitamin C levels after 12 weeks in either group. Mean levels
of plasma CRP and IL-6 were not significantly different after the intervention.

Table 5: Serum vitamin C and inflammatory markers at baseline and 12 weeks
Control group n=25
Baseline

12 weeks

Intervention group n=24
Baseline

12 weeks

IL6 (pg/mL)a

4.3±2.9

6.3±5.8

3.7±1.8

3.8±3.5

hsCRP (mg/L)b

2.0±2.5

2.0±2.3

1.6±1.5

1.7±1.8

Vitamin C (uM)

19.3±13.1

13.6±8.2

18.2±10.6

13.3±11.0

a

IL-6 Interleukin-6; bhsCRP C-Reactive Protein

Data are given as mean ± SD.
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Discussion
This study found that daily consumption of a feasible serving of anthocyanin-rich cherry
juice for 12 weeks improved cognitive performance across almost all tasks in older adults
with mild to moderate dementia. To our knowledge, this is the first controlled human trial
examining cognitive and physical responses to a dietary intervention involving sweet cherries
as a source of flavonoids and anthocyanins.

Our study suggests that provision of anthocyanins through an achievable and acceptable daily
quantity of sweet cherry juice over 12 weeks has benefit for cognitive function in older adults
with Alzheimer’s type dementia. Trends are evident, showing improvements in cognitive
performance across all tasks with regular cherry juice consumption. Statistically significant
improvements are seen for category verbal fluency and tasks relating to verbal learning and
memory (Figure 2). The moderate and large effect sizes seen for the cognitive tasks highlight
the clinical relevance of these cognitive improvements. These findings are consistent with
those of recent human and animal studies showing improvement in cognitive performance in
these domains with dietary supplementation with other anthocyanin-rich food sources (11-13,
31-33). Although, we have previously shown that intake of cherry juice does not impact acute
cognition over 6h (34). The ability of flavonoids to modulate Alzheimer’s disease
progression is still poorly understood (17). As explored by the hypothesis in the current
study, flavonoids may be more likely to hinder both normal and disease-related losses in
cognitive performance through their actions on the brain's cellular and molecular architecture
of memory, rather than halt disease progression.

Some nutritional differences existed between the intervention and control juices (Table 2). As
intended, the ORAC measure of oxidative capacity (3200 vs 15.55 µmol TE/g) and the red

pigment (anthocyanin) content (690mg/L vs 0.2mg/L) is much higher in the experimental
cherry juice compared to the control apple juice. Apple juice was chosen as a control juice as
it represents a commonly consumed beverage in older adults, but that has negligible
anthocyanin. Despite literature indicating beneficial effects of apples and apple flavonoids for
health outcomes, the juice utilised in the experiment was processed in a way that likely
degraded the flavonoid content. This important aspect of the research design is relevant to
translation of the findings into dietary messages. However, it is important for future work to
investigate whether dose-response effects are evident in such nutrition interventions.

Despite randomisation, differences in several anthropometric and nutritional factors existed
between the intervention and control group at baseline (Table 1). The estimation of total
flavonoid intake and intake of specific flavonoid subclasses at baseline revealed large
variability between subjects. This can be principally attributed to variations in tea (confirmed
by significant differences in caffeine intake between groups), wine and other fruit juice
consumption, which were the main sources of flavonoids in this sample. Total intake and
major sources of flavonoids of participants at baseline was similar to that reported for
Australians aged 65+ years (510 vs 575 vs 683mg/day respectively) (4, 35, 36). The higher
anthocyanin intake in our sample, compared to national estimates, may be explained by a
relatively high consumption of red wine in the study group. The addition of cherry juice to
the diet of the intervention group provided them with an additional 138mg anthocyanin/day,
which increased their total anthocyanin intake to 46 times greater than the national estimate
for the daily intake of adults aged 65+y (3.02mg/day). In the absence of a Nutrient Reference
Value (NRV) for flavonoids (37), this magnitude of increase in consumption can be
considered to be a significant increase above habitual intake levels for this age group.

Secondary outcome measures included anti-inflammatory effects, changes in functional and
physical ability and depressive symptomatology. There was a significant reduction in systolic
blood pressure and a trend for diastolic blood pressure in the intervention group; however the
study was not adequately powered to detect blood pressure changes. Previous intervention
trials have hypothesised that the mechanisms relating to the improvements seen in cognitive
performance after anthocyanin-rich food supplementation are due to a reduction in
inflammatory markers, resulting in a blood pressure-lowering effect (13). Our study showed
that markers of inflammation were not significantly altered after cherry juice supplementation
(Table 5) and remained within the clinically normal ranges (CRP <5mg/mL; IL-6
<10pg/mL). This finding suggests that the bioactive components provided by the cherry juice
may provide other benefits, such as stimulating an up-regulation of signalling cascades in
areas of the brain relating to memory (8). Additionally, as Alzheimer’s disease is associated
with progressive and chronic inflammation (38), the disease pathology may mask any
potential anti-inflammatory effects provided by the cherry juice.

Surprisingly, serum vitamin C levels decreased in both groups at 12 weeks of follow up
(Table 5). This difference cannot be explained through changes in dietary patterns over the
study duration as vitamin C intake did not differ according to 24h diet recall data.
Additionally, self-reported fruit and vegetable intake was not significantly different at
baseline and follow up. A possible explanation may be the study juices may have replaced
consumption of commercial fruit juices that could have been fortified with high levels of
ascorbic acid. The reported reduction in serum vitamin C parameters is not clinically
significant as mean levels remained in the clinically normal range (11-114 micromoles/L).
Although under-researched in humans, some pre-clinical evidence indicates that high-doses
of flavonoids may inhibit ascorbate absorption (39), which may explain the reduction in

serum vitamin C. Alternatively, the reagents that were utilized to prepare the serum prior to
Vitamin C analysis may have degraded over the study period.

The study limitations include a relatively small sample size and short intervention length (12
weeks). However, preclinical studies indicate that flavonoids from berry fruits may require
only several weeks to accumulate in brain regions associated with cognition (40). Despite
this, a short time frame limits our ability for observations regarding changes in dementia
progression. Given the moderate to large effect sizes found in this study, a longer duration of
follow up with larger numbers would be the next progression in research. Another limitation
of the study relates to the generally better cognitive and physical ability of the intervention
group, which is evident despite randomisation. Interestingly, the measure of effect for
improvements on cognitive tasks in the intervention group was the same, regardless of the
cognitive ability of participants. At the baseline and 12 week visits, a standardised breakfast
meal was provided, however at the 6 week visit participants arrived at the clinic facility in a
non-fasted state, after having consumed their usual breakfast at home (as a fasting blood
sample was not collected). If there was a large difference in the nutritional composition of
their usual breakfast to the standardised breakfast (e.g. a significantly greater intake of
caffeine), this may have either positively or negatively influenced cognitive performance at
this time point. However, this effect was minimised by the participants consuming their
breakfast at 6 and 12 weeks ad-libitum, and as the improvements in cognitive performance
seen at 6 and 12 weeks are not significantly different, a difference in breakfast is unlikely to
be of great importance. Lastly, while it is likely the bioactivity of the cherry juice relates to
its high anthocyanin content, the potential bioactive effects of other polyphenols cannot be
excluded.

Regardless of their exact mechanisms, the potential of flavonoids to improve cognitive
outcomes for older adults with Alzheimer’s type dementia cannot be underestimated and a
notable strength of this study is the very low possibility of any harm to this vulnerable group.
Further research is required to improve the knowledge base to inform dietary
recommendations for this patient group, as an adjunct to traditional dementia treatment. For
older adults living with reduced cognitive capacity, the inclusion of an anthocyanin-rich
beverage, in addition to or in replacement of another processed fruit juice, may be a practical
way to improve their total flavonoid consumption, which has been shown to provide positive
outcomes for prevention of cognitive decline.

Conclusion
The findings of this study suggest that regular anthocyanin-rich cherry juice consumption
over 12 weeks can improve cognition in older adults with dementia and provides a basis for
more comprehensive human trials to study the potential of cherry flavonoids to influence
neuro-cognitive health.
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